Deferoxamine put into the spinal fluid for people whose cancer has spread to the lining around the brain and spinal cord

Official title: A Study of Deferoxamine (DFO) in People With Leptomeningeal Metastasis

Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.

The trial team last updated this record on .

The short version

This study is testing whether a drug called deferoxamine is safe when it is put straight into the fluid around the brain and spinal cord.

Read our full plain-language summary

What the trial team says

The researchers are doing this study to find out whether deferoxamine (DFO) given intrathecally (directly into the CSF) is a safe treatment for people with leptomeningeal metastasis from solid tumor cancer. The researchers will test different doses of DFO to find the highest dose that causes few or mild side effects. When the dose is found, they will test it in future participants to see whether DFO is a safe and effective treatment for people with leptomeningeal metastasis from solid tumor malignancies. They are also doing this study to see how the body absorbs, distributes, gets rid of, and responds to DFO.

From the trial's own listing on ClinicalTrials.gov.

Key facts

Registry number
NCT05184816
Stage of testing
Phase 1
Conditions studied
Leptomeningeal Metastases

Where it is running

This trial lists 7 sites.

How to use this

Talk to your care team first. They know your history and can tell you whether this trial is worth your time.

Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.

See the full listing on ClinicalTrials.gov

This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.